AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer
09 August 2023 - 11:00PM
Renovaro BioSciences Inc. (NASDAQ:RENB) (formerly NASDAQ:
ENOB), an advanced, pre-clinical biotechnology firm in
cell, gene and immunotherapy focused on solid tumors with short
life expectancy, has executed a binding, exclusive letter
of intent to merge a subsidiary with the cutting-edge health
AI company GEDi Cube Intl Ltd. The combined company would
aim to accelerate diagnosis, enhance treatment effectiveness,
discover new therapies,
and expand access to life-saving technologies
for cancer and other diseases.
“I have been privileged to lead life sciences
groups at Intel, Oracle, and most recently, NVIDIA,” said Craig
Rhodes, CEO of GEDi Cube International Ltd. “But GEDi
Cube's remarkably innovative technology developed over nearly a
decade has already validated earlier diagnoses of lung cancer
in humans at a leading university hospital and created the
technology for 12 additional cancers, including pancreatic and
breast cancer, which is very inspiring and exciting."
"We are rapidly expanding our technologies to
include other cancers and diseases," Rhodes added. "I believe that
uniting with Renovaro BioSciences’ potential solid
tumor therapies is not merely synergistic. It could also create a
multiplier effect to expedite diagnosis, improve treatment
outcomes and discover, in silico, new therapies to improve
many lives.”
"Renovaro, Latin for 'renewal,' represents our
company’s mission,” Renovaro Biosciences CEO Dr.
Mark Dybul said. “Our advanced cell, gene and
immunotherapy techniques are designed to reinvigorate the body’s
natural tumor-fighting mechanisms. I believe joining
forces with GEDi Cube could enhance the efficacy of our
upcoming trials and speed up the discovery of novel treatment
approaches, thereby extending our life-saving technology to more
cancer patients and renewing hope for them and their
families,” Dr. Dybul added.
While Renovaro's current results focus on
pancreatic cancer, it plans to include other solid tumors with
short life-expectancy in the first in human Phase I/IIa studies
that are in track to start by mid-2024. The rates of these cancers
and other serious health conditions are rising rapidly as many
populations are growing older. As a concrete example of a potential
multiplier effect, GEDi Cube’s AI technology could potentially
enable the combined Company to focus upcoming human trials on the
cancers most likely to respond to therapy, expand the database of
key markers for earlier diagnosis and disease progression and
discover new generations of Renovaro’s treatment approach as well
as entirely new therapies.
Dr. Anahid Jewett is a leading cancer
immunotherapy researcher at UCLA who has conducted
independent, pivotal studies with Renovaro’s technology in
different animal models. She has consistently demonstrated
80% to 90% pancreatic tumor reduction in size and weight that was
correlated with significant enhancement of key aspects of the
immune response. “After decades as a scientist searching for
the best ways to translate laboratory studies into life-saving
treatments, I am very excited about the possibilities of uniting
advanced AI with some of the most promising results we have seen
in our pancreatic cancer models with Renovaro’s
technology," Dr. Jewett said. "To me, this is the future of
medicine.”
FORWARD-LOOKING STATEMENT
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties,
including but not limited to the success or efficacy of our
pipeline. All statements other than historical facts are
forward-looking statements, which can be identified by the use of
forward-looking terminology such as “believes,” “plans,” “expects,”
“aims,” “intends,” “potential,” or similar expressions. Actual
events or results may differ materially from those projected in any
of such statements due to various uncertainties, including as set
forth in Renovaro BioSciences Inc. (NASDAQ: RENB) most recent
Annual Report on Form 10-K filed with the SEC. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and Renovaro Biosciences, Inc. undertakes no
obligation to revise or update this shareholder letter to reflect
events or circumstances after the date hereof.
For more information on Renovaro Biosciences Inc. go to their
website at www.renovarobio.com.
For more information on GEDi Cube Intl LTD, go to their website
at www.gedicube.com.
Source: Renovaro Biosciences
|
|
|
Press Contact: |
|
IR@Renovarobio.com |
|
|
IR@Gedicube.com |
Renovaro (NASDAQ:RENB)
Historical Stock Chart
From Apr 2024 to May 2024
Renovaro (NASDAQ:RENB)
Historical Stock Chart
From May 2023 to May 2024